Ramakrishnan S - Search Results

1

Anti-graft-versus-host disease effect of DT390-anti-CD3sFv, a single-chain Fv fusion immunotoxin specifically targeting the CD3 epsilon moiety of the T-cell receptor.

Vallera DA, Panoskaltsis-Mortari A, Jost C, Ramakrishnan S, Eide CR, Kreitman RJ, Nicholls PJ, Pennell C, Blazar BR. Vallera DA, et al. Among authors: ramakrishnan s. Blood. 1996 Sep 15;88(6):2342-53. Blood. 1996. PMID: 8822957 Free article.

2

Gene therapy of murine solid tumors with T cells transduced with a retroviral vascular endothelial growth factor--immunotoxin target gene.

Jin N, Chen W, Blazar BR, Ramakrishnan S, Vallera DA. Jin N, et al. Among authors: ramakrishnan s. Hum Gene Ther. 2002 Mar 1;13(4):497-508. doi: 10.1089/10430340252809793. Hum Gene Ther. 2002. PMID: 11874628

3

Adeno-associated virus-mediated delivery of a mutant endostatin in combination with carboplatin treatment inhibits orthotopic growth of ovarian cancer and improves long-term survival.

Subramanian IV, Bui Nguyen TM, Truskinovsky AM, Tolar J, Blazar BR, Ramakrishnan S. Subramanian IV, et al. Among authors: ramakrishnan s. Cancer Res. 2006 Apr 15;66(8):4319-28. doi: 10.1158/0008-5472.CAN-05-3297. Cancer Res. 2006. PMID: 16618757

4

Sickle cell anemia as a possible state of enhanced anti-apoptotic tone: survival effect of vascular endothelial growth factor on circulating and unanchored endothelial cells.

Solovey A, Gui L, Ramakrishnan S, Steinberg MH, Hebbel RP. Solovey A, et al. Among authors: ramakrishnan s. Blood. 1999 Jun 1;93(11):3824-30. Blood. 1999. PMID: 10339489 Free article.

5

Recombinant hybrid toxin with dual enzymatic activities. Potential use in preparing highly effective immunotoxins.

Li BY, Ramakrishnan S. Li BY, et al. Among authors: ramakrishnan s. J Biol Chem. 1994 Jan 28;269(4):2652-8. J Biol Chem. 1994. PMID: 8300596 Free article.

6

A novel method to purify immunotoxins from free antibodies using modified recombinant toxins.

Dhanabal M, Fryxell DK, Ramakrishnan S. Dhanabal M, et al. Among authors: ramakrishnan s. J Immunol Methods. 1995 Jun 9;182(2):165-75. doi: 10.1016/0022-1759(95)00036-a. J Immunol Methods. 1995. PMID: 7790724

7

Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo.

Ramakrishnan S, Olson TA, Bautch VL, Mohanraj D. Ramakrishnan S, et al. Cancer Res. 1996 Mar 15;56(6):1324-30. Cancer Res. 1996. PMID: 8640821

8

Targeting the tumor vasculature: inhibition of tumor growth by a vascular endothelial growth factor-toxin conjugate.

Olson TA, Mohanraj D, Roy S, Ramakrishnan S. Olson TA, et al. Among authors: ramakrishnan s. Int J Cancer. 1997 Dec 10;73(6):865-70. doi: 10.1002/(sici)1097-0215(19971210)73:6<865::aid-ijc17>3.0.co;2-3. Int J Cancer. 1997. PMID: 9399667

9

Separation of function between the domains of toxic shock syndrome toxin-1.

Wahlsten JL, Ramakrishnan S. Wahlsten JL, et al. Among authors: ramakrishnan s. J Immunol. 1998 Jan 15;160(2):854-9. J Immunol. 1998. PMID: 9551921

10

Antitumor response elicited by a superantigen-transmembrane sequence fusion protein anchored onto tumor cells.

Wahlsten JL, Mills CD, Ramakrishnan S. Wahlsten JL, et al. Among authors: ramakrishnan s. J Immunol. 1998 Dec 15;161(12):6761-7. J Immunol. 1998. PMID: 9862706

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,559 results

Search Page

Filters